DOCSLIB.ORG

1996 Annual-Report.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

GENENTECH BUSINESS DEVELOPMENT A third component of Genentech’s four-point strategy for growth is to continue to accelerate the pace of forming strategic alliances. Significant new alliances made in 1996 and early 1997, and key progress made within ear- lier alliances, show how well planned partnerships with the right fit can con- tribute significantly to Genentech’s success. Partnering for Success The joint Genentech/ From new technologies, to new products, to new avenues for Genentech IDEC/Roche project team science, Genentech’s partners in business build on the company’s for the C2B8 antibody existing strengths meets to prepare to file Genentech’s strategy for business development is to access partners’ resources that for U.S. and European build on Genentech’s strengths. Genentech has a clear, three-pronged approach: regulatory clearance to market the antibody for First, the company seeks to license late-stage products that can augment its product the treatment of non- portfolio and contribute to rev- Hodgkin’s B-cell lym- enues near term. An example is phoma. The filing, Genentech’s collaboration with achieved in the first IDEC to develop IDEC’s C2B8 quarter of 1997, followed antibody. Another is the agree- from successful Phase III ment with Roche for Genentech results announced in to promote Roferon-A in the December 1996. The United States for its approved collaboration with IDEC cancer indications. stems from Genentech’s Second, Genentech partners with Business Development companies to access emerging group’s efforts to license technologies. Genentech’s late-stage products that relationship with Incyte can provide near-term Pharmaceuticals, for example, provides access to a powerful DNA sequence and gene market opportunities. In expression database. And a relationship with Baxter Healthcare Corporation combines 1996, Roche opted to Genentech’s understanding of Factor VIII* with Baxter’s experience in cellular therapy. develop the C2B8 anti- body outside the Third, Genentech seeks partnerships to realize the value of its own promising prod- United States. ucts it chooses not to develop itself. With the wealth of products from Genentech’s discovery research efforts, these relationships are essential to help keep Genentech scientists motivated and ensure promising new medicines are developed. Two exam- ples are Genentech’s anti-CD11a antibody (hu1124), for which XOMA is developing the manufacturing process necessary to support development and is conducting clinical trials, and the anti-CD18 antibody, for which Roche is conducting clinical trials, each in collaboration with Genentech. Through such relationships, Genentech mini- mizes the impact on its clinical resources yet maintains significant product rights. Miya Weber (photo above), 43, was diagnosed with non-Hodgkin’s B-cell lymphoma in early 1995 after she found a lump in her armpit. After her cancer did not respond to chemotherapy, she enrolled in the Phase III clinical trial for the C2B8 antibody in October 1995. Miya felt better within weeks. She had a complete response and was able to return to work as a probation officer. * Genentech conducted the initial research and development that led to the recombinant Factor VIII now on the market for treating hemophilia. 35 Genentech’s Partners Genentech’s collaborations include: Alkermes — collaboration involving the development Massachusetts General Hospital — collaborative of a sustained release formulation of Genentech’s research agreement for basic developmental research human growth hormone. conducted at the hospital’s Cardiovascular Research Center through studies of zebrafish. Baxter — collaboration to jointly develop encapsu- lated cell therapy for hemophilia A. Novartis/Tanox — agreement to develop and commercialize anti-IgE monoclonal antibodies. Boehringer Ingelheim — collaboration to jointly develop TNK for treatment of acute myocardial Roche — collaborations include: promoting of infarction. Roferon®-A for oncology indications, developing Genentech’s anti-CD18 monoclonal antibody for Cambridge Antibody Technology — collaborative treatment of hemorrhagic shock, manufacturing a research agreement based on CAT antibody TNF-receptor fusion protein being studied by Roche, engineering technology. and small molecule discovery collaborations focusing Connective Therapeutics — agreements for on antagonists to IIb/IIIa, LFA/ICAM, VLA 4/VCA M, Connective to develop relaxin for the treatment of and certain coagulation targets. connective tissue disorders and other indications, Scios — collaboration agreement for the development and to develop interferon gamma to treat certain of Auriculin® anaritide for the treatment of oliguric dermatological diseases. acute renal failure. CytoTherapeutics — collaborative agreement to Sensus — agreement for Sensus to develop growth hor- develop neurotrophic factors in CytoTherapeutics’ cell mone antagonists for treating certain growth disorders. encapsulation technology to treat certain neurodegen- erative diseases. Tularik — agreement for Tularik to develop novel human therapeutics based on transcription factors. Genetics Institute — agreement to provide Genentech with access to the DiscoverEase™ library VaxGen (formerly GenenVax) — agreement for of secreted proteins. VaxGen to develop gp120, a potential prophylactic AIDS vaccine. Hoechst AG — collaboration to develop small Washington University — exclusive licensing molecule vitronectin receptor antagonists for treat- agreement for neurturin, a protein which is believed ment of chronic bone disorders. to promote nerve cell growth and protect certain IDEC Pharmaceuticals — collaboration to jointly nerve cells against damage. develop IDEC’s anti-CD20 monoclonal antibodies for Xenova — joint discovery and development program the treatment of non-Hodgkin’s B-cell lymphomas. for small molecules in the cardiovascular, growth Immunex — exclusive license to Genentech for the control, inflammation and autoimmune disease areas. LERK proteins for neurobiology uses. XOMA — collaborative agreement to jointly develop Incyte Pharmaceuticals — agreement providing Genentech’s anti-CD11a monoclonal antibody for Genentech access to Incyte’s LifeSeq® DNA sequence treatment of psoriasis and organ transplant rejection. and gene expression database. 36 Business Highlights GENENTECH BUSINESS HIGHLIGHTS IN 1996 AND EARLY 1997 Corporate • 1996 earnings: $118.3 million, or 96 cents • Named J. Richard Munro as chairman of per share. 1996 revenues: $968.6 million. the board of directors following cofounder Robert A. Swanson’s retirement as • A Delaware Chancery Court approved the chairman and from the board. settlement of a consolidated stockholder class action lawsuit filed following the • Filed an amended complaint alleging that 1995 announcement of an extended buy- Novo-Nordisk infringes five Genentech out option by Roche, which stockholders patents in the manufacture and sale of approved in October 1995. In the settle- Novo’s recombinant human insulin prod- ment, Roche agreed to an increase in the uct, Novolin®, in the United States. redemption prices for Genentech’s stock by 50 cents each quarter, with a final redemption price of $82.50 in the quarter Marketed Products ending June 30, 1999, if Roche causes the Activase® (Alteplase, recombinant) redemption of the remaining Genentech stock under the extended buyout option. • 1996 Activase sales: $284.1 million. • Celebrated 20th anniversary since • Reached a record thrombolytic market Genentech’s founding by Herbert W. share of approximately 80 percent. Boyer, Ph.D. and Robert A. Swanson. • Received U.S. regulatory clearance to mar- • Roche exercised its options, per ket Activase for the treatment of eligible Genentech’s 1995 arrangement with adult patients with acute ischemic stroke Roche, to develop the following within three hours of symptom onset. Genentech development products outside • The American Heart Association, the the United States: IDEC’s C2B8 mono- American Academy of Neurology and the clonal antibody, insulin-like growth factor-I National Institutes of Health issued guide- (IGF-I), and nerve growth factor (NGF). lines or proposed standards identifying • Completed a new 42,000-square-foot stroke as a medical emergency and building to provide three floors of recommending that eligible patients— research labs and offices for Cell following appropriate screening—be treat- Culture/Fermentation R&D groups. ed with Activase to enhance their chances of recovering with no or minimal disability. 5 • Filed a patent infringement suit against Pulmozyme® Boehringer Mannheim in the United (dornase alfa) Inhalation Solution States and Germany that alleges its • 1996 Pulmozyme sales: $76.0 million. thrombolytic agent, Reteplase, infringes several Genentech patents. • Received U.S. regulatory clearance to market Pulmozyme for the management • Reached an out-of-court settlement with of cystic fibrosis patients with advanced Sumitomo Pharmaceuticals in Japan on a disease. seven-year patent dispute over t-PA, for which Sumitomo agreed to halt the man- Actimmune® (Interferon gamma-1b) ufacturing and marketing of the drug in exchange for Genentech foregoing • 1996 Actimmune sales: $4.5 million. demands related to damages. • Discontinued pursuing Actimmune for renal cell carcinoma after analysis of ® Protropin (somatrem for injection), Phase III clinical data showed no signifi- ® Nutropin [somatropin (rDNA origin) cant benefit of the product for this for injection] and Nutropin AQ™ targeted indication. [somatropin (rDNA origin)
Recommended publications
  • GH/IGF-1 Abnormalities and Muscle Impairment: from Basic Research to Clinical Practice

    GH/IGF-1 Abnormalities and Muscle Impairment: from Basic Research to Clinical Practice

    International Journal of Molecular Sciences Review GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice Betina Biagetti * and Rafael Simó * Diabetes and Metabolism Research Unit, Vall d’Hebron Research Institute and CIBERDEM (ISCIII), Universidad Autónoma de Barcelona, 08193 Bellaterra, Spain * Correspondence: [email protected] (B.B.); [email protected] (R.S.); Tel.: +34-934894172 (B.B.); +34-934894172 (R.S.) Abstract: The impairment of skeletal muscle function is one of the most debilitating least understood co-morbidity that accompanies acromegaly (ACRO). Despite being one of the major determinants of these patients’ poor quality of life, there is limited evidence related to the underlying mechanisms and treatment options. Although growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels are associated, albeit not indisputable, with the presence and severity of ACRO myopathies the precise effects attributed to increased GH or IGF-1 levels are still unclear. Yet, cell lines and animal models can help us bridge these gaps. This review aims to describe the evidence regarding the role of GH and IGF-1 in muscle anabolism, from the basic to the clinical setting with special emphasis on ACRO. We also pinpoint future perspectives and research lines that should be considered for improving our knowledge in the field. Keywords: acromegaly; myopathy; review; growth hormone; IGF-1 1. Introduction Acromegaly (ACRO) is a rare chronic disfiguring and multisystem disease due to Citation: Biagetti, B.; Simó, R. non-suppressible growth hormone (GH) over-secretion, commonly caused by a pituitary GH/IGF-1 Abnormalities and Muscle tumour [1].
  • Growth Hormone Booklet

    Growth Hormone Booklet

    GROWTH HORMONE AND PRADER-WILLISECOND EDITION SYNDROME A REFerence For FaMILies and Care ProViders Donald G. Goranson, Jr., Editor Growth Hormone and Prader-Willi Syndrome — Second Edition Published By: Prader-Willi Syndrome Association (Usa) 8588 Potter Park Drive, Suite 500 Sarasota, Florida 34238 Toll Free: 800-926-4797 Local: 941-312-0400 Fax: 941-312-0142 www.pwsausa.org © Copyright 2011 A Reference for Families and Care Providers Growth HORMONE AND PraderSECOND-WILLI EDITION Syndrome A REFerence For FaMILies and Care ProViders Donald G. Goranson, Jr., Editor Growth Hormone and Prader-Willi Syndrome — Second Edition A Reference for Families and Care Providers CONTENTS Acknowledgments....................................................................... 5 Introduction and History .............................................................. 7 Prader-Willi Syndrome and Growth ...................................................... 9 Effects of Growth Hormone Treatment in Children with PWS ................................ 20 What Is Involved in Growth Hormone Treatment? .......................................... 26 Questions, Wisdom and Survey Data from our Families ..................................... 34 Appendix: A. Overview of Prader-Willi Syndrome................................................ 40 B. Information Resources on Prader-Willi Syndrome .................................... 42 C. Information Resources on Growth Hormone Use and Products ........................ 43 D. Glossary of Terms ............................................................
  • Fully Human Domain Antibody Therapeutics: the Best of Both Worlds

    Fully Human Domain Antibody Therapeutics: the Best of Both Worlds

    Drug Discovery Fully Human Domain Antibody Therapeutics: The Best of Both Worlds By combining the therapeutic benefits of small molecule drugs with those of fully human antibodies, Domain Antibodies are expected to have strong therapeutic and commercial potential. By Robert Connelly at Domantis Robert Connelly is Chief Executive Officer of Domantis. He has over 22 years’ commercial experience of the life science sector, including that gained in the fields of diagnostics, drug discovery technologies and antibody therapeutics. Prior to joining Domantis, he was CEO of Veritas Pharmaceuticals (Los Angeles, USA), an in vivo imaging start-up company. He spent over five years with IGEN International, latterly as Senior Vice President and General Manager, Life Sciences, where he took part in the company’s IPO and financing rounds, raising $130 million. The first 11 years of his career were spent at Abbott Laboratories in sales, marketing and management positions. Domain Antibodies (dAbs) are the smallest functional variable regions of either the heavy (VH) or light (VL) binding units of antibodies. At Domantis, we are chains of human antibodies. Domantis scientists applying our proprietary know-how in dAbs to deliver have used the variable domains sequences of human human therapies that address large, unmet medical antibodies to create a series of large and highly needs in areas such as inflammation, cancer and functional libraries of fully human dAbs, with each autoimmune diseases. Three and a half years after library comprising at least 1010 different dAbs. The opening our laboratories, we have a dozen proprietary dAbs selected from these libraries are both specific therapeutic programmes underway, and an additional for their biological target and are well folded and eight therapeutic programmes with partners.
  • Moderna Appoints Oncology Leader Dr. Stephen Kelsey As President of Onkaido

    Moderna Appoints Oncology Leader Dr. Stephen Kelsey As President of Onkaido

    Moderna Appoints Oncology Leader Dr. Stephen Kelsey as President of Onkaido Former Genentech executive to lead Moderna’s first venture company, focused exclusively in novel biology for oncology drug development CAMBRIDGE, Mass., July 1, 2014— Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) TherapeuticsTM, a revolutionary treatment modality to enable the in vivo production of therapeutic proteins, announced today that Stephen Kelsey, M.D., will become president of Onkaido Therapeutics, Moderna’s oncology drug development company, effective July 21. Launched in January of this year, Onkaido is Moderna’s first venture company, focused exclusively on developing and commercializing mRNA-based oncology treatments. “As we continue to grow Moderna and perfect our mRNA Therapeutics platform, we are also focused on building a transformational oncology company that will benefit patients and society. This requires hiring the best oncology talent to lead Onkaido,” said Stéphane Bancel, president and founding chief executive officer, Moderna. “Steve brings a wealth of experience in oncology drug development to his new role. His knowledge and leadership, combined with the team of Onkaido scientists and Moderna’s innovative mRNA technology, will help speed a new class of cancer drugs to patients around the world.” Dr. Kelsey has extensive pharmaceutical industry experience in oncology. After 16 years as an academic clinician, he started his industry career at Sugen, and later was vice president of hematology/oncology at Genentech. While at Genentech, Dr. Kelsey played a significant role in the development of key products Perjeta®, Kadcyla® and Erivedge®, as well as other molecules in the company’s oncology portfolio. He left Genentech in 2009 to run Geron’s oncology division, where he served for four years as executive vice president, research and development, and chief medical officer helping to develop therapeutics and vaccines to fight cancer.
  • Power List 2018

    Power List 2018

    APRIL 2018 # 40 Editorial Upfront In My View Sitting Down With Stop and look at how far Preparing for the EU’s new What can algae teach us Sophie Kornowski-Bonnet, the industry has come data protection regulation about medicine design? Roche Partnering 09 10 – 11 20 – 21 50 – 51 100 Power List 2018 www.themedicinemaker.com Continuous Growth Fibra-Cel® disks—3-D growth matrix for perfusion and continuous processes Suspend your disbelief: > Less susceptible to shear forces, The three-dimensional Fibra-Cel matrix clogging, and fouling entraps anchorage dependent and > Ideal for secreted product and vaccine suspension cells—for optimized growth production conditions and increased yields. > Suitable for GMP production > For use in autoclavable, sterilize-in- place or BioBLU® Single-Use Vessels www.eppendorf.com/Fibra-Cel Fibra-Cel® is a registered trademark owned by Imerys Minerals California, Inc., USA and licensed to Eppendorf, Inc., USA. Eppendorf®, the Eppendorf Brand Design and BioBLU® are registered trademarks of Eppendorf AG, Germany. All rights reserved, including graphics and images. Copyright © 2018 by Eppendorf AG. tmm_epp_ad_210x266_2018_04.indd 1 28.03.18 13:34 Online this Month The Power List The 2018 Power List, starting on page 24 of this issue, features 100 of the most inspirational professionals involved in A Scientist Walks into a Bar... format to the public”. Generally, drug development. The list was compiled it involves scientists speaking on a based on reader nominations and And gives a presentation as part variety of topics, from medicine, to feedback from a judging panel – but any of Pint of Science, a global science neuroscience, to robotics and more, in list will always be subjective.
  • Growth Hormone Deficiency and Other Indications for Growth Hormone Therapy – Child and Adolescent

    Growth Hormone Deficiency and Other Indications for Growth Hormone Therapy – Child and Adolescent

    TUE Physician Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY – CHILD AND ADOLESCENT 1. Medical Condition Growth Hormone Deficiency and other indications for growth hormone therapy (child/adolescent). 2. Diagnosis 1. Medical History Growth hormone deficiency (GHD) is a result of dysfunction of the hypothalamic-pituitary axis either at the hypothalamic or pituitary levels. The prevalence of GHD is estimated between 1:4000 and 1:10,000. GHD may be present in combination with other pituitary deficiencies, e.g. multiple pituitary hormone deficiency (MPHD) or as an isolated deficiency. Short stature, height more than 2 SD below the population mean, may represent GHD. Low birth weight, hypothyroidism, constitutional delay in growth puberty, celiac disease, inflammatory bowel disease, juvenile arthritis or other chronic systemic diseases as well as dysmorphic phenotypes such as Turner’s syndrome and genetic diagnoses such as Noonan’s syndrome and GH insensitivity syndrome must be considered when evaluating a child/adolescent for GHD. Pituitary tumors, cranial surgery or radiation, head trauma or CNS infections may also result in GHD. Idiopathic short stature (ISS) is defined as height below -2 SD score (SDS) without any concomitant condition or disease that could cause decreased growth (ISS is an acceptable indication for treatment with Growth Hormone in some but not all countries). Failure to treat children with GHD can result in significant physical, psychological and social consequences. Since not all children with GHD will require continued treatment into adulthood, the transition period is very important. The transition period can be defined as beginning in late puberty the time when near adult height has been attained, and ending with full adult maturation (6-7 years after achievement of adult height).
  • Print Layout 1

    Print Layout 1

    TECHNICAL PROGRAM Monday, March 19 5:00 – 8:00 pm Welcome Reception Tuesday, March 20 8:00 – 10:00 Session 1: Setting the Conference Context and Drivers Chair: Geoff Slaff (Amgen) Roger Perlmutter (Amgen) Conquering the Innovation Deficit in Drug Discovery Helen Winkle (CDER, FDA) Regulatory Modernization 10:00 – 10:30 Break Vendor and poster review 10:30 – 12:30 Session 2: Rapid Cell Line Development and Improved Expression System Development Chairs: Timothy Charlebois (Wyeth) and John Joly (Genentech) Amy Shen (Genentech) Stable Antibody Production Cell-Line Development with an Improved Selection Process and Accelerated Timeline Mark Leonard (Wyeth) High-Performing Cell-Line Development within a Rapid and Integrated Platform Process Control Pranhitha Reddy (Amgen) Applying Quality-by-Design to Cell Line Development Lin Zhang (Pfizer) Development of a Fully-Integrated Automated System for High-Throughput Screening and Selection of Single Cells Expressing Monoclonal Antibodies 12:30 – 2:00 Lunch Vendor and poster review 2:00 – 4:30 Session 3: High-Throughput Bulk Process Development Chairs: Brian Kelley (Wyeth) and Jorg Thommes (Biogen Idec) Colette Ranucci (Merck) Development of a Multi-Well Plate System for High-Throughput Process Development Min Zhang (SAFC Biosciences) CHO Media Library – an Efficient Platform for Rapid Development and Optimization of Cell Culture Media Supporting High Production of Pharmaceutical Proteins in Chinese Hamster Ovary Cells Nigel Titchener-Hooker The Use of Ultra-Scale-Down Approaches to Enable Rapid Investigation
  • Genentech Tocilizumab Letter of Authority June 24 2021

    Genentech Tocilizumab Letter of Authority June 24 2021

    June 24, 2021 Hoffmann-La Roche, Ltd. C/O Genentech, Inc. Attention: Dhushy Thambipillai Regulatory Project Management 1 DNA Way, Bldg 45-1 South San Francisco, CA 94080 RE: Emergency Use Authorization 099 Dear Ms. Thambipillai: This letter is in response to Genentech, Inc.’s (Genentech) request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for the emergency use of Actemra1 (tocilizumab) for the treatment of coronavirus disease 2019 (COVID-19) in certain hospitalized patients, as described in the Scope of Authorization (Section II) of this letter, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes coronavirus disease 2019 (COVID-19).2 On the basis of such determination, the Secretary of HHS on March 27, 2020, declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to Section 564 of the Act (21 3 U.S.C. 360bbb-3), subject to terms of any authorization issued under that section. Actemra is a recombinant humanized monoclonal antibody that selectively binds to both soluble and membrane-bound human IL-6 receptors (sIL-6R and mIL-6R) and subsequently inhibits IL- 6-mediated signaling through these receptors.
  • List of Section 13F Securities

    List of Section 13F Securities

    List of Section 13F Securities 1st Quarter FY 2004 Copyright (c) 2004 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2004, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2004. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f)(1) and Rule 13f-1 thereunder.
  • Adult Growth Hormone Deficiency

    Adult Growth Hormone Deficiency

    A Guide for Patients • Patients should be sure to inject Nutropin at a different recommended place on their body each time to avoid tissue breakdown. A doctor or nurse should provide injection training and supervise the fi rst injection • The use of Nutropin therapy has not been studied in patients over 65 years of age. Elderly patients may be more sensitive to Nutropin therapy and may experience more side effects with Adult • Patients with Turner syndrome should be monitored closely by a doctor for ear infections and cardiovascular problems during Nutropin therapy Growth Hormone Defi ciency What are common possible side effects of Nutropin therapy? Common side effects reported in adults and children taking Nutropin therapy include injection site reactions. Additional common side effects in adults include swelling, For easily accessible answers, education, joint pain, and carpal tunnel syndrome. and support, visit Nutropin.com You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech or call 1-866-NUTROPIN (1-866-688-7674). at (888) 835-2555. How should you store Nutropin? 14 Nutropin must be kept refrigerated (36° to 46°F [2° to 8°C]). Do not freeze. NuSpin 15 pens must be used within 28 days of initial use. Throw away any unused Nutropin after 28 days of initial use. Before giving an injection, check the manufacturer’s expiration date on the pen. Do not use if it has expired. Do not inject medication if the solution is cloudy. Your healthcare team is your primary source of information about your treatment.
  • In Adults with Growth Hormone Deficiency

    In Adults with Growth Hormone Deficiency

    NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA64; Human growth hormone (somatropin) in adults with growth hormone deficiency This guidance was issued in August 2003. The review date for this guidance is ‘within 6 months’ of the publication of trial data according to the last review update in May 2012. 1. Recommendation TA64 should be moved to the static list. That we consult on this proposal. 2. Original remit(s) To appraise the clinical and cost-effectiveness of human growth hormone in its licensed indications for the treatment of growth hormone deficiency in adults. 3. Current guidance 1.1 Recombinant human growth hormone (somatropin) treatment is recommended for the treatment of adults with growth hormone (GH) deficiency only if they fulfil all three of the following criteria. They have severe GH deficiency, defined as a peak GH response of less than 9 mU/litre (3 ng/ml) during an insulin tolerance test or a cross- validated GH threshold in an equivalent test. They have a perceived impairment of quality of life (QoL), as demonstrated by a reported score of at least 11 in the disease-specific 'Quality of life assessment of growth hormone deficiency in adults' (QoL- AGHDA) questionnaire. They are already receiving treatment for any other pituitary hormone deficiencies as required. 1.2 The QoL status of people who are given GH treatment should be re-assessed 9 months after the initiation of therapy (an initial 3-month period of GH dose titration, followed by a 6-month therapeutic trial period). GH treatment should be discontinued for those people who demonstrate a QoL improvement of less than 7 points in QoL-AGHDA score.
  • Human Growth Hormone Page 1 of 60

    Human Growth Hormone Page 1 of 60

    Human Growth Hormone Page 1 of 60 Medical Policy Title: Human Growth Hormone Prior Authorization IS REQUIRED by the Member’s Contract Prior Authorization Form: BCBSKS reviews the Prior Authorization requests http://www.bcbsks.com/CustomerService/Forms/pdf/15-811_Growth_Hormone_PA.pdf Link to Drug List (Formulary): http://www.bcbsks.com/drugs/ Professional Institutional Original Effective Date: February 4, 1986 Original Effective Date: August 18, 2008 Revision Date(s): January 30, 2014; Revision Date(s): January 30, 2014; December 9, 2014; June 23, 2015; December 9, 2014; June 23, 2015; December 8, 2015; January 1, 2017; December 8, 2015; January 1, 2017; May 24, 2017; August 18, 2017; May 24, 2017; August 18, 2017; December 20, 2017; December 5, 2018; December 20, 2017; December 5, 2018; October 1, 2019; January 1, 2020; October 1 2019; January 1, 2020; October 1, 2020 October 1, 2020 Current Effective Date: January 1, 2020 Current Effective Date: January 1, 2020 State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact Blue Cross and Blue Shield of Kansas Customer Service. The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy. The medical policies do not constitute medical advice or medical care.